Silence Therapeutics is a London-based pharmaceutical company formed in 1994. The company has pioneered the development of short-interfering ribonucleic acid therapeutics for the treatment of rare diseases. From Wikipedia
The injectable drug, targeting lipoprotein(a), moves to Phase 3 trials to assess its impact on cardiovascular events, with no serious adverse effects reported.
